Ventyx BiosciencesVTYX
VTYX
About: Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Employees: 75
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% more funds holding
Funds holding: 116 [Q2] → 118 (+2) [Q3]
9% more call options, than puts
Call options by funds: $314K | Put options by funds: $288K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
7.43% less ownership
Funds ownership: 81.7% [Q2] → 74.26% (-7.43%) [Q3]
14% less capital invested
Capital invested by funds: $133M [Q2] → $114M (-$18.6M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
168%
upside
Avg. target
$7.50
235%
upside
High target
$9
302%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target | 168%upside $6 | Neutral Reiterated | 11 Nov 2024 |
Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target | 302%upside $9 | Outperform Reiterated | 8 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
Neutral
GlobeNewsWire
1 month ago
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Negative
Seeking Alpha
1 month ago
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.
Positive
Zacks Investment Research
2 months ago
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
Positive
Benzinga
2 months ago
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
Neutral
GlobeNewsWire
3 months ago
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.
Neutral
GlobeNewsWire
3 months ago
Ventyx Biosciences Announces Departure of Chief Financial Officer
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
Neutral
GlobeNewsWire
3 months ago
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
4 months ago
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024
Negative
Benzinga
4 months ago
Dow Edges Lower; Ventyx Biosciences Shares Plummet
U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday.
Charts implemented using Lightweight Charts™